Published within
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
...
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
NewsWire
|
PharmaMar, a biopharmaceutical subsidiary of Zeltia SA, has completed enrolment for the randomised Phase IIb trial in resistant/refractory ovarian cancer with PM01183 versus Topotecan.
Published By MarketLine
|
20 May 2013 |
|
NewsWire
|
Corgenix Medical Corporation, a provider of in vitro diagnostic products, has received CE mark notification for the company's ReLASV antigen rapid test for Lassa fever diagnosis.
Published By MarketLine
|
20 May 2013 |
|
NewsWire
|
Eisai Europe Ltd., the UK subsidiary of Eisai Co., Ltd., has filed an application with the European Medicines Agency, or EMA, for anticancer agent Halaven, or eribulin mesylate, requesting an indication expansion of eribulin to contribute to earlier-line treatment of patients with metastatic breast cancer.
Published By MarketLine
|
20 May 2013 |
|
NewsWire
|
Osiris Therapeutics, Inc., a stem cell therapeutic company, has reported that net loss for the first quarter ended March 31, 2013 was $2.73 million, or $0.08 loss per share, compared to a net loss of $1.27 million or $0.04 loss per share, for the same quarter ended March 31, 2012.
Published By MarketLine
|
20 May 2013 |
|
NewsWire
|
ArthroCare Corp., a medical device company, has reported that net income available to common stockholders for the first quarter ended March 31, 2013 was $10.27 million, or $0.30 per share, compared to $12.08 million, or $0.36 per share, for the same quarter ended March 31, 2012.
Published By MarketLine
|
20 May 2013 |
|
NewsWire
|
Perrigo Company, a provider of over-the-counter and generic prescription pharmaceuticals, has reported that net income for the third quarter ended March 30, 2013 was $111.92 million, or $1.18 per diluted share, compared to $115.73 million, or $1.23 per diluted share, for the same quarter ended March 31, 2012. For fiscal 2013, the company expects earnings to be in the range of $4.67 and $4.87 per diluted share.
Published By MarketLine
|
20 May 2013 |
|
NewsWire
|
Jazz Pharmaceuticals plc, a specialty biopharmaceutical company, has reported that net income for the first quarter ended March 31, 2013 was $43.42 million, or $0.71 per diluted share, compared to $27.68 million, or $0.48 per diluted share, for the same quarter ended March 31, 2012. For 2013, the company expects GAAP net income per diluted share to be in the range of $3.32 to $3.69 and revenues to be in the range of $830 million to $860 million.
Published By MarketLine
|
20 May 2013 |
|
NewsWire
|
Bristol-Myers Squibb Company and AstraZeneca have reported the results from a 12-month sub-group analysis of a National Institutes of Health, or NIH, open-label, long-term research study of metreleptin, an investigational agent for the treatment of metabolic disorders associated with inherited or acquired lipodystrophy, or LD.
Published By MarketLine
|
20 May 2013 |
|
NewsWire
|
CML HealthCare Inc., a provider of laboratory and medical imaging services, has entered into a partnership with Inflamax Research Inc., a contract research organization, to provide clinical research and bioanalytical services to the pharmaceutical and biotechnology industry.
Published By MarketLine
|
20 May 2013 |
|
NewsWire
|
Cubist Pharmaceuticals, Inc., a biopharmaceutical company, has received fast track status from the FDA for the company's late-stage antibiotic candidate ceftolozane/tazobactam in the previously granted Qualified Infectious Disease Product, or QIDP, indications, Hospital-Acquired Bacterial Pneumonia, or HABP, /Ventilator-Associated Bacterial Pneumonia, or VABP, and Complicated Urinary Tract Infections, or cUTI.
Published By MarketLine
|
20 May 2013 |
|
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
...
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.